Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Isis Lipid-Lowering Drug Shows Benefit In Phase II For Familial Hypercholesterolemia

This article was originally published in The Pink Sheet Daily

Executive Summary

Isis 301012 shows treatment benefit as an add-on therapy to statins and other drugs.

You may also be interested in...



Isis Lipid-Lowering Candidate Named Mipomersen; Firm Projects Smaller Loss

Firm revises net operating loss guidance downward by roughly $20 million.

Isis Lipid-Lowering Candidate Named Mipomersen; Firm Projects Smaller Loss

Firm revises net operating loss guidance downward by roughly $20 million.

Isis Makes Quick Gain From Ortho-McNeil Pact, Enters Phase I For Novel Diabetes Candidate

Firm also will present positive Phase II data on novel small molecule targeting apolipoprotein B-100 for treatment of familial hypercholesterolemia later this week.

Topics

UsernamePublicRestriction

Register

LL1135490

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel